Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference
04:05pm, Monday, 05'th May 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Tuesday, May 13
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
10:15am, Monday, 05'th May 2025
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to Decline
11:07am, Wednesday, 30'th Apr 2025
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025
04:05pm, Wednesday, 23'rd Apr 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 7, 2025, after the close of the U.S. financ
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 11'th Apr 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 3, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted in
Acadia (ACAD) Stock Jumps 6.1%: Will It Continue to Soar?
10:35am, Thursday, 10'th Apr 2025
Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Acadian upgraded to Equal Weight from Underweight at Morgan Stanley
05:17am, Monday, 07'th Apr 2025
Morgan Stanley upgraded Acadian Asset Management to Equal Weight from Underweight with a price target of $26, up from $25. The company's skew to overseas assets will insulate its possible downside to
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?
12:36pm, Friday, 28'th Mar 2025
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 14'th Mar 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 5, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted in
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
04:05pm, Thursday, 13'th Mar 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the following virtual investor conferences: UBS Virtual CNS Day 2025 Fireside Chat: M
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from the open-label study, DAFFODIL™, evaluating the safety, tolerabilit
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised)
07:40am, Wednesday, 05'th Mar 2025
Acadia Pharmaceuticals (ACAD) came out with fourth-quarter earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.28 per share a year ago
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)
05:10am, Tuesday, 04'th Mar 2025
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.
Acadia Pharmaceuticals Ends FY2024 On Solid Footing
05:19am, Sunday, 02'nd Mar 2025
ACADIA Pharmaceuticals reported its fourth quarter results this week and provided initial guidance for FY2025, highlighting key financial metrics and future projections. The company continues to see s
Acadia Pharmaceuticals to Participate in the TD Cowen's 45th Annual Health Care Conference
04:05pm, Thursday, 27'th Feb 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference on Wednesday, March
